Amlodipine-FA tablet,low dose group — Competitive Intelligence Brief

Amlodipine-FA tablet,low dose group (Amlodipine-FA tablet,low dose group) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Calcium channel blocker. Area: Cardiovascular.

phase 2 Calcium channel blocker L-type calcium channels Cardiovascular Small molecule

Target snapshot

Amlodipine-FA tablet,low dose group (Amlodipine-FA tablet,low dose group) — Shenzhen Ausa Pharmed Co.,Ltd. Amlodipine-FA is a calcium channel blocker that works by relaxing blood vessels and reducing blood pressure.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Amlodipine-FA tablet,low dose group TARGET	Amlodipine-FA tablet,low dose group	Shenzhen Ausa Pharmed Co.,Ltd	phase 2	Calcium channel blocker	L-type calcium channels
Treatment R	Treatment R	Boryung Pharmaceutical Co., Ltd	marketed	Calcium channel blocker	L-type calcium channels
Verapamil + paroxetine	Verapamil + paroxetine	University of California, Irvine	marketed	SSRI + calcium channel blocker combination	P-glycoprotein (MDR1/ABCB1), L-type calcium channels
Calcium Channel Blockers, ACE-Inhibitor	Calcium Channel Blockers, ACE-Inhibitor	University of Aarhus	marketed	Combination antihypertensive (calcium channel blocker + ACE inhibitor)	L-type calcium channels; Angiotensin-converting enzyme (ACE)
Magnesium sulfate IV	Magnesium sulfate IV	University of Liege	marketed	Electrolyte supplement / anticonvulsant	NMDA receptor, L-type calcium channels
Rate-control therapy	Rate-control therapy	Our Lady of the Lake Hospital	marketed	AV nodal blocking agents (beta-blockers, non-dihydropyridine calcium channel blockers, or cardiac glycosides)	AV nodal conduction (multiple targets depending on agent: beta-1 adrenergic receptors, L-type calcium channels, or adenosine receptors)
Nifedipine/Telmisartan	Nifedipine/Telmisartan	Bayer	marketed	Calcium channel blocker + Angiotensin II receptor blocker combination	L-type calcium channels; AT1 angiotensin II receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Calcium channel blocker class)

1. Shenzhen Ausa Pharmed Co.,Ltd · 2 drugs in this class
2. Boryung Pharmaceutical Co., Ltd · 2 drugs in this class
3. Ain Shams University · 1 drug in this class
4. Bioprojet · 1 drug in this class
5. Bristol-Myers Squibb · 1 drug in this class
6. GlaxoSmithKline · 1 drug in this class
7. Handok Inc. · 1 drug in this class
8. Hasten Biopharmaceutical Co., Ltd. · 1 drug in this class
9. Hospital de Clinicas de Porto Alegre · 1 drug in this class
10. Laboratorios Richmond S.A.C.I.F. · 1 drug in this class